Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02235493 · ClinicalTrials.gov registry record
Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09
A clinical trial, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- 6
- Enrollment target
NCT02235493: Completed study, sponsored by Alexion Pharmaceuticals.
NCT02235493 is a clinical trial that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02235493 has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the natural history of HPP in patients with Juvenile-onset HPP who served as historical controls in ENB-006-09.
Primary Outcome
The MPOMA-G is a 5-component assessment that is used to evaluate gait performance. The first component has 4 sub-components. For 2 components and 2 sub-components, scores of 0 or 1 are assigned while scores of 0, 1 or 2 are assigned to the rest of the 2 components and 2 sub-components based on type of ambulation pattern observed. The maximum total score of 12 points = no impairment and 0 points = worst impairment.
Interventions
- BIOLOGICAL Retrospective Case Only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-09 |
What the finished NCT02235493 record still lists
NCT02235493 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Retrospective Case Only is the first listed.
NCT02235493 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02235493 about?
NCT02235493 is a clinical study titled "Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09". The purpose of this study is to characterize the natural history of HPP in patients with Juvenile-onset HPP who served as historical controls in ENB-006-09.
What is the current status of trial NCT02235493?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2014-08. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02235493?
The interventions under investigation include: Retrospective Case Only (BIOLOGICAL).
Who is sponsoring clinical trial NCT02235493?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia